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Background & aims 
Cancer-associated fibroblasts (CAFs) are a major component of the tumor microenvironment 
in colorectal cancer (CRC). CAFs play an important role in tumor progression and metastasis, 
partly through the transforming growth factor-β (TGF-β) signaling pathway. We investigated 
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CAF-specific endoglin expression was investigated in resection specimens from CRC patients 
using immunohistochemistry and related to metastases-free survival. In vitro, endoglin-
mediated invasion was assessed in transwell invasion experiments, using primary CRC-
derived CAFs. In a zebrafish model for CRC, involvement of CAF-specific endoglin expression 
on tumor cell invasion was investigated. Finally, effects on metastatic spread were assessed 
in a mouse model for experimental liver metastasis. 
 
Results 
CAFs specifically at invasive borders of CRC, express endoglin with increasing intensity 
through increasing stage. Additionally, endoglin-expressing CAFs were detected in lymph 
node and liver metastases from the same patients, suggesting a role in CRC metastasis 
formation. In stage-II CRC, CAF-specific endoglin expression at the invasive front positively 
correlated with metastasis-free survival. In vitro experiments revealed that endoglin is 
indispensable for bone morphogenetic protein (BMP)-9-induced signaling and fibroblast 
survival. CAF invasion in vitro was inhibited by targeting endoglin using the endoglin 
neutralizing antibody TRC105. In zebrafish, endoglin-expressing fibroblasts enhanced 
colorectal tumor cell infiltration into the liver and decreased survival. Finally, endoglin 




Endoglin-expressing CAFs contribute to CRC progression and metastasis. Treatment with 
TRC105 inhibits CAF invasion and tumor metastasis, indicating an additional target beyond 












Colorectal cancer (CRC) is the third most common cancer worldwide and accounts for 8,5% 
of all cancer deaths1. Ninety percent of all cancer patients die because of metastatic spread 
to distant organs. Therefore, patients identified to be at risk to develop metastatic disease 
(stage-III/IV) receive adjuvant (chemo)-radiation therapy2. Early stage patients are not 
adjuvantly treated, but a significant group still develops metastatic disease, emphasizing that 
better understanding of the mechanism underlying tumor metastasis is needed. 
Next to malignant epithelial cells, the tumor stroma can make up to 50% of the tumor mass 
and is predictive for CRC patient survival3. The tumor stroma, or tumor microenvironment 
(TME), is composed of vascular endothelial cells, immune cells and cancer-associated 
fibroblasts (CAFs)4. CAFs interact with all other cells in the TME via direct cell-cell contacts 
and CAF-derived cytokines5, 6. This leads to tumor progression and ultimately metastasis7. 
Therefore, CAFs are considered a potential target for novel cancer therapies.  
Transforming growth factor-β (TGF-β) is capable of transdifferentiating resident fibroblasts 
into CAFs8, 9, indicated by increased expression of α-smooth muscle actin (αSMA) and 
fibroblast activation protein (FAP)10. Endoglin is a co-receptor for TGF-β and bone 
morphogenetic protein (BMP)-9 which is highly expressed on the surface of activated 
endothelial cells and indispensable during embryogenesis11-13. In endothelial cells, binding of 
TGF-β or BMP-9 to endoglin induces Smad1 phosphorylation14. Furthermore, endoglin 
microvessel density was correlated with tumor progression and metastases in CRC15, 16. 
Consequently, the endoglin neutralizing antibody TRC105 is currently under clinical 
development as a novel anti-angiogenic therapy. TRC105 binds human endoglin with high 
affinity, prevents BMP-9 binding17 and induces antibody-dependent cell-mediated 
cytotoxicity18, 19. 
Although endoglin in endothelial cells has been extensively studied, expression on other cells 
in the TME is less known. Therefore, we have investigated the role of endoglin expression on 
CAFs. We showed that CAFs, specifically at invasive borders of colorectal tumors and in 
metastatic lesions, express endoglin. Next, we assessed regulation of endoglin expression in 
CAFs and its role in CAF invasion in vitro. The involvement of CAF-specific endoglin 
expression in tumor invasion was studied in a novel zebrafish model for CRC. Finally, in a 
mouse model for liver metastasis, we assessed the effects of therapeutically targeting 
endoglin on CAF-regulated metastatic spread to the liver. Taken together, our data suggest 
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an additional working mechanism for endoglin targeted therapy on CAFs, besides targeting 




Materials and methods 
Patient samples 
Paraffin-embedded tissue samples were obtained from the Department of Pathology, Leiden 
University Medical Center (LUMC) and were used according to the guidelines of the Medical 
Ethical Committee of the LUMC. The first cohort consisted of 25 adenomas, 104 stage-II and 
94 stage-III treatment naive CRC and the same number of adjacent normal tissue samples. 
The second cohort consisted of 31 patients of which resection specimens of the primary 
tumor, lymph node and liver metastases were present. Patient characteristics and >10 year 
follow-up were available. 
 
Tissue analysis 
Immunohistochemical and -fluorescent stainings were performed as described before20, 21, 
using antibodies as shown in supplementary table S1. CAF-specific endoglin expression, was 
scored on a scale of 1 to 4 (≤10%; 10-25%; 25-50% and ≥50% positive) in a blinded manner 
by two independent observers. Pictures were obtained using a Leitz Diaplan microscope 
(Leitz, Wetzlar, Germany). Quantitative PCR analyses were performed as described before6 
using primer sequences described in supplementary table S2. 
 
Cell culture and signaling assays 
Human CAFs and the mouse CRC cell line MC3822 were cultured in DMEM/F12, 
supplemented with 10% fetal calf serum (FCS), 10 mM HEPES, 50 μg/mL gentamycin, 
100 IU/mL penicillin and 100 μg/mL streptomycin (PenStrep, all ThermoFisher). The 
immortalized HUVEC cell line ECRF23 was cultured as described before24. Human embryonic 
kidney 293 (HEK293T) cells were maintained in DMEM, supplemented with 10% FCS and 
PenStrep (all ThermoFisher). Primary human CAFs were isolated from non-necrotic parts of 
the tumors and normal fibroblasts (NFs) from adjacent healthy tissue as described before6. 
Tissues were cultured in complete DMEM/F12 with 2.5 μg/mL Fungizone (ThermoFisher). 
Mouse CAFs were isolated from CRC tissue by culturing 5x5 mm pieces of tumor in 
DMEM/F12 as described above. For both human and mouse isolations, fibroblast-like cell 
outgrowth was observed after 7-10 days. Murine embryonic fibroblasts (MEFs) were 
obtained from E12.5 embryos as described before25 from endoglin floxed mice26. MEFs were 
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maintained in DMEM, supplemented with 10% FCS and PenStrep (all ThermoFisher). All cell 
cultures were monthly tested for mycoplasma contamination. 
Constructs expressing human endoglin27, Cre recombinase (pLV.mPGK.iCRE.IRES.PuroR, 
kindly provided by Dr. M. Gonçalves, LUMC) or endoglin short hairpin RNA (shRNA, Sigma 
Mission shRNA library, constructs SHC001, TRCN0000083138, TRCN0000083139, 
TRCN0000083140, TRCN0000083141 and TRCN0000083142) were delivered by lentiviral 
transduction to 80% confluent fibroblasts or endothelial cells. After 48 hours, transduced 
cells were selected using 1.5 µg/mL puromycin. HEK293T cells were grown to 80% 
confluency and transfected with endoglin expressing plasmids using 1 mg/mL 
polyethylenimine (PEI; Polysciences Inc., Warrington, PA, USA). 
For signaling assays, fibroblasts were seeded in six-well plates. Upon 90% confluency, cells 
were serum starved overnight in medium containing 40 μg/mL TRC105 (Tracon 
Pharmaceuticals, San Diego, CA, USA) or 40 μg/mL human IgG (BioXCell, West Lebanon, NH, 
USA) for human cells. Mouse fibroblasts were incubated in the presence of 40 μg/mL M1043 
(Abzena, Cambridge, UK) or 40 μg/mL Rat IgG (BioXCell). Next day, cells were stimulated 
with either 5 ng/mL TGF-β328, 0.1 ng/mL BMP-9 (R&D systems) or 100 ng/mL BMP-6 
(PeproTech, London, UK ) for one hour. Cells were lysed in RIPA buffer, protein content was 
determined and western blot analysis was performed as described before29. Membranes 
were incubated overnight with primary antibodies against endoglin, phosphorylated 
(p)Smad1 or pSmad2. Blots were stripped and reprobed with mouse anti-GAPDH or anti-
actin antibodies (supplementary table S1) as loading control. Blots were developed using the 
Bio-Rad ChemiDoc Touch Imaging System (Bio-Rad, Veenendaal, The Netherlands). 
 
Invasion assays 
One thousand HEK293T cells or 2500 CAFs were seeded on top of 0.6% agarose (Sigma, 
Zwijndrecht, The Netherlands) coated 96-well plates and left to form spheroids for 48h. 
Next, spheroids were collected and embedded in 1 mg/mL collagen-I matrix (Advanced 
BioMatrix, San Diego, CA, USA) containing 10% FCS. At 0, 24 and 48 hours, pictures were 
taken using a Zeiss Axiovert 200M microscope (Carl Zeiss BV, Sliedrecht, The Netherlands). 
Quantification of the invaded area was performed using Adobe Photoshop software.  
For transwell invasion assays, the upper surface of 8.0 µm pore size ThinCert (Greiner Bio-
One, Alphen aan den Rijn, The Netherlands) was coated with 200 µg/mL collagen-I in culture 
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medium containing 0.5% FCS. The lower compartment of the transwell system contained 
medium with 0.5% FCS and 0.1 ng/mL BMP-9 or 5 ng/mL TGF-β3. When invasion towards 
CRC cells was assessed, 2*105 HT29, HCT116 or MC38 cells were seeded in the lower well. 
2.5*104 fibroblasts were seeded on the coated inserts in medium containing 0.5% FCS and 
left to invade for 24 hours, in the presence of ligands and inhibitors as described above. 
After 24 hours, invaded cells were fixed with 4% paraformaldehyde and stained with crystal 
violet. Using an Olympus BX51TF microscope (Olympus Life Science Solutions, Zoeterwoude, 
The Netherlands), five pictures per insert were obtained at 2x magnification. Cell invasion 
was quantified in at least three independent experiments by counting the number of 
invaded cells or percentage of positive stained area using Image J software (National 
Institutes of Health, USA). 
 
Zebrafish 
Zebrafish were maintained according to standard methods approved by the Leiden 
University animal welfare committee. Two-day old Tg(fli1:GFP)30 dechorionated zebrafish 
embryos were injected with 400 cells in the heart cavity: either 400 dTomato-labeled MC38 
cells or 200 dTomato-labeled MC38 combined with 200 unlabeled MEFs. After injection, 
embryos were maintained at 34°C. Fluorescent imaging was performed using a Leica TCS SPe 
confocal microscope (Leica Microsystems, Son, The Netherlands) under sedation with 
0.003% tricaine (Sigma, Zwijndrecht, The Netherlands). Confocal stacks were processed 
using Leica software. For survival analysis, embryos were injected and transferred to a 48-
well culture plate and viability was monitored daily for 6-12 days. 
 
Experimental metastasis model 
Animal experiments were approved by the Dutch animal ethics committee. 20-weeks old 
Crl:CD-1Fox1nu male mice (Charles River, L’Arbresie Cedex, France) were injected 
intrasplenic with 5*105 HT29 cells expressing firefly luciferase under isoflurane anesthesia, 
either alone or combined with 105 CAFs. CAFs were pre-treated with 40 µg/mL TRC105 or 40 
µg/mL human IgG. Mice were treated twice weekly, with 15 mg/kg TRC105 or 15 mg/kg 
human IgG, intraperitoneally. Metastatic spread was monitored twice weekly using 
bioluminescent imaging on the IVIS Lumina-II (Caliper Life Sciences, Hopkinton, MA, USA). 25 
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Differences between two groups were calculated using Students’ t-test, for multiple groups 
one-way ANOVA analysis was used. Survival curves were generated using Kaplan-Meier 
analysis and Log rank test. Differences in bioluminescent signals over time were calculated 





Endoglin expression on CAFs correlates with metastasis-free survival in stage-II CRC 
To investigate endoglin expression in CRC, sequential slides of CRC tissues were stained for 
cytokeratin (epithelium), CD31 (endothelial cells), αSMA (CAFs) and endoglin. As previously 
described, endoglin is highly expressed on angiogenic endothelial cells, as shown by the 
overlap between CD31 and endoglin staining (Fig. 1A, white arrow heads). However, we also 
observed endoglin expression on CAFs at the invasive borders, as indicated by co-staining of 
endoglin and αSMA (Fig. 1A, black arrow heads). Endoglin expression by CAFs was further 
confirmed using immunofluorescent double staining (Fig. 1B and supplementary Fig. S1). 
Notably, fibroblasts in adjacent normal colonic tissue or CAFs at the tumor core did not 
express endoglin (Fig. 1C). This specific localization of endoglin-expressing CAFs at the 
invasive border and their absence in the tumor core suggest that endoglin on CAFs plays a 
role in CRC invasion and metastasis.  
Exploring this hypothesis, we stained primary CRC, lymph node and liver metastases from 
the same patients for endoglin and αSMA (Fig. 2A). Endoglin expression was present on CAFs 
at the invasive border of primary tumors, while staining intensity was remarkably higher on 
CAFs in both lymph node and liver metastases (Fig. 2A). To assess CAF-specific endoglin 
expression throughout different CRC stages, we stained normal colonic tissue, polyps and 
stage-II and –III CRC patient tissues for αSMA and endoglin. Average scores for endoglin-
expressing CAFs increased with tumor stage (Fig. 2B). To determine whether CAF-specific 
endoglin expression could be predictive for developing metastatic disease, we assessed the 
relation between endoglin expression and metastasis-free survival. In stage-II CRC, high CAF-
specific endoglin expression significantly correlated with worse metastasis-free patient 
survival (Fig. 2C). In stage-III CRC, no relation between metastases-free survival and CAF-
specific endoglin expression was observed (supplementary Fig. S2). These data indicate that 
CAF-specific endoglin expression is predictive for metastasis-free survival in stage-II CRC. 
 
Normal fibroblasts and CAFs display similar receptor expression profiles in vitro 
In order to characterize TGF-β signaling in CAFs, we isolated normal fibroblasts (NF) and CAFs 
from CRC patients. CAFs were isolated from CRC tissues and NF from adjacent normal 
mucosa (>10 cm from primary tumor) from four different patients and gene expression was 
assessed. Endoglin expression did not differ between NFs and CAFs from the same patient, 
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or between patients (supplementary table S3). Although NFs in tissue do not express 
endoglin (supplementary Fig. S3), during in vitro culturing endoglin expression is highly 
upregulated. Since endoglin can bind multiple TGF-β family members and mediate 
downstream signaling, expression of various TGF-β/BMP receptors was determined 
(supplementary table S3). No differences in expression levels were observed between 
patients or between NFs and CAFs from the same patient. Although platelet derived growth 
factor receptor (PDGFR) expression can be used to distinguish certain CAF subpopulations31, 
no clear distinction in PDGFR expression was observed in NFs or CAFs from these patients in 
vitro (supplementary table S3). 
 
Endoglin expression on fibroblasts is indispensable for BMP-9-induced signaling 
Canonical TGF-β signaling is regulated through different type-I receptors. Recruitment of 
ALK1, in the presence of endoglin, results in Smad1/5/8 phosphorylation, whereas ALK5 
directs phosphorylation of Smad2/3. Therefore, we determined endoglin signaling and 
downstream transcriptional regulation after TGF-β or BMP-9 stimulation. TGF-β stimulation 
of high endoglin-expressing human CAFs resulted in increased expression of the Smad2/3 
target gene PAI-1, whereas this was unaffected by BMP-9 stimulation (Fig. 3A). BMP-9 
induced expression of the Smad1 target gene inhibitor of differentiation-1 (ID-1). TGF-β also 
induced ID-1 expression, probably via ALK1 (Fig. 3A). Endoglin mRNA expression was not 
affected by TGF-β or BMP-9 stimulation (Fig. 3A). BMP-9 stimulation resulted in fast and 
strong Smad1 phosphorylation, whereas TGF-β stimulation slightly affected Smad1 
phosphorylation (Fig. 3B). Next, the experiment was repeated in CAFs expressing very low 
levels of endoglin. In these CAFs, TGF-β-mediated effects were similar as observed for high 
endoglin-expressing CAFs (Fig. 3C). BMP-9 stimulation, however, did not induce ID-1 gene 
expression (Fig. 3C) nor Smad1 phosphorylation (Fig. 3D), confirming endoglin-dependency. 
Endoglin expression was unaffected by ligand stimulation (Fig. 3C and 3D). Mouse CAFs, 
highly expressing endoglin, showed similar gene expression results as observed in high 
endoglin-expressing human CAFs (Fig. 3E and 3F). Furthermore, BMP-9 induced strong 
Smad1 phosphorylation, whereas TGF-β increased Smad2 phosphorylation in these cells (Fig. 
3F). Together, these results show that endoglin is crucial for BMP-9-induced signaling in both 




Endoglin is required for in vitro CAF survival 
After characterizing endoglin-mediated signaling in CAFs, its functional role was further 
evaluated. Short hairpin RNA (shRNA) constructs targeting endoglin were introduced using 
lentiviral transduction. Knockdown efficiency of the constructs at RNA and protein level was 
confirmed in endothelial cells (supplementary Fig. S4) and showed reduced endoglin 
expression of 40-90% compared to non-targeting control. Endoglin knockdown did not affect 
endothelial cell morphology or survival (Fig. 3G). When CAFs were transduced with endoglin 
shRNA constructs, proliferation ceased and cells started to adopt a senescent phenotype 
(Fig. 3G), progressing into in cell detachment and death. This phenotype was confirmed in 
two CAFs and normal fibroblasts (data not shown), implying that endoglin is indispensable 
for CAF survival in vitro. 
In order to interfere with endoglin signaling in CAFs we used the endoglin neutralizing 
antibody TRC105. Human CAFs were stimulated with TGF-β, BMP-9 or BMP-6 in the 
presence or absence of TRC105. Stimulation with TGF-β increased Smad2 and, to a lesser 
extent, Smad1 phosphorylation, independent of TRC105 (Fig. 3H). BMP-9 stimulation 
strongly increased Smad1 phosphorylation, which was abrogated by TRC105. BMP-6 induces 
endoglin-independent Smad1 phosphorylation, and was therefore unaffected by TRC105. In 
mouse CAFs, stimulation with BMP-9 strongly induced Smad1 phosphorylation (Fig. 3I). This 
was efficiently blocked by the mouse endoglin neutralizing antibody M1043, whereas TGF-β-
induced Smad2 phosphorylation was unaffected (Fig. 3I). TRC105 also inhibited Smad1 
phosphorylation, although to a lesser extent (data not shown). Therefore, subsequent 
experiments using mouse cells were performed using M1043. Together, these results 
confirm that BMP-9-induced Smad1 phosphorylation is endoglin-dependent in CAFs and this 
can be inhibited using endoglin neutralizing antibodies. 
 
Endoglin regulates CAF invasion in vitro 
In both endothelial and non-endothelial cells, different roles for endoglin in cell migration 
have been reported. Ectopic expression of endoglin in HEK293T cells enhanced cell invasion 
into a collagen-I matrix (supplementary Fig. S5). Spheroid diameter remained similar, 
suggesting that invasion rather than proliferation is the main determinant of this effect. 
Next, we examined the role of endoglin in CAF invasion. High endoglin-expressing CAFs (F2) 
were compared to CAFs expressing 200-fold lower levels of endoglin (F1, Fig. 4A). After 48 
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hours F2 CAFs invaded a collagen-I matrix to a higher extent than F1 CAFs (Fig. 4B), 
suggesting a role for endoglin in CAF invasion. To further confirm this, we overexpressed 
endoglin in F1 CAFs (Fig. 4C), and invasive capacity was determined using transwell invasion 
assays through collagen-I coated inserts. Quantification of the number of invaded cells after 
24 hours showed that endoglin overexpression significantly increased basal CAF invasion 
(Fig. 4D). Since endoglin knockdown is not possible in CAFs, we used murine embryonic 
fibroblasts (MEFs) isolated from endoglin fl/fl mouse embryos26. To induce knock out (KO), 
MEFs were transduced with Cre recombinase or an empty vector. Endoglin KO did not affect 
MEF proliferation and cells remained viable for up to three passages after transduction. 
Endoglin mRNA levels were reduced by 90% (Fig. 4E and supplementary Fig. S6), and 
transwell invasion assays showed significantly reduced invasion by endoglin KO MEFs (Fig. 
4F). These data demonstrate the importance of endoglin in CAF invasion. 
 
Endoglin targeting reduces invasive properties of fibroblasts 
To confirm that CAF invasion is dependent on ligand binding to endoglin, and note merely on 
its presence, invasive capacity of mouse CAF was assessed in the presence of M1043. M1043 
treatment reduced basal mouse CAF invasion, whereas BMP-9- and TGF-β-induced invasion 
were inhibited to a similar level, albeit not statistically significant (Fig. 5A). Since interactions 
in the TME can be mediated by paracrine signaling, we assessed CAF invasion towards MC38 
mouse CRC cells. First, we showed that MC38 stimulate CAF invasion to a similar extent as 
BMP-9, which could not be further enhanced by combining MC38 with BMP-9 
(supplementary Fig. S7A). M1043 treatment significantly decreased MC38-induced CAF 
invasion, compared with an IgG control (Fig. 5B). In human CAFs, TRC105 decreased basal 
human fibroblast invasion (Fig. 5C). Since BMP-9 and TGF-β failed to increase CAF invasion in 
this case, TRC105 treatment showed similar effects as observed under basal conditions, 
although not statistically significant (Fig. 5C). In co-culture experiments, treatment with 
TRC105 significantly inhibited HCT116- and HT29-induced CAF invasion (Fig. 5D and 
supplementary Fig. S7B). Taken together, these experiments imply a substantial role for 
endoglin/BMP-9 signaling in CAF invasion in vitro. 
 
Endoglin expression on fibroblasts promotes CRC liver invasion in zebrafish 
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To study the role of CAF-specific endoglin in tumor metastasis in a multicellular model, we 
developed a zebrafish model for CRC. In short, fluorescently labeled MC38 cells, in the 
presence or absence of MEFs, were injected in the heart cavity of zebrafish embryos and fish 
were followed over time. Solid tumor-like structures were formed and induced angiogenesis 
(Fig. 6A). Co-injection of MC38 with MEFs significantly decreased fish survival (Fig. 6B), 
probably due to compromised liver function caused by tumor cell invasion. Histological 
analysis revealed the vimentin-positive MC38 cells invading into the liver in both groups, 
although liver invasion was observed at earlier time points in the co-injected group (Fig. 6C). 
To investigate endoglin-dependency, MC38 were injected in combination with normal or 
endoglin KO MEFs. Tumor formation and angiogenesis were not affected (supplementary 
Fig. S8). However, fish survival markedly improved when endoglin KO MEFs were co-injected 
and resembled survival of fish injected with MC38 alone (Fig. 6D). Integration of MEFs in the 
tumors of both co-injected groups was confirmed by staining for mouse-specific αSMA 
expression (Fig. 6E). These data indicate that endoglin expression on MEFs affects CRC cell 
invasion in zebrafish. 
 
Endoglin targeting inhibits CRC liver metastasis in mice  
Finally, we assessed therapeutic targeting of endoglin in an experimental mouse model for 
CRC liver metastasis. HT29 cells were injected in the spleen, alone or in combination with 
human CAFs. Mice were treated (Fig. 7A) and metastatic spread was monitored using 
bioluminescent imaging (BLI). TRC105 treatment did not affect metastatic spread in mice 
injected with HT29 cells alone (data not shown). In mice co-injected with HT29 and CAFs 
TRC105 significantly reduced BLI signal from the liver (Fig. 7B), indicating that TRC105 affects 
metastasis formation by directly targeting CAFs. Metastatic lesions in the liver were 
visualized using ex vivo BLI upon termination of the experiment (Fig. 7C). 
(Immuno)histochemical staining revealed no morphological differences in liver metastases 
between groups (Fig. 7D). These data show that targeting endoglin on CAFs inhibits 
metastatic spread of HT29 CRC cells and imply CAFs as an additional target cell for TRC105.  
 
Discussion 
In this study, we show that CAF-specific endoglin expression is predictive for the 
development of metastatic disease in stage-II CRC and endoglin-expressing CAFs are 
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detected in metastatic lesions of CRC patients. CAF-specific endoglin expression stimulates 
CAF invasion in vitro and tumor cell invasion and metastasis in a novel zebrafish model and 
an in vivo model for CRC. 
Endoglin is crucial for vascular development as underlined by embryonic lethality of endoglin 
knockout mice11-13. Our current study shows the importance of endoglin for fibroblast 
survival in vitro. Romero and colleagues reported the inability to culture primary prostate 
CAFs isolated from endoglin heterozygous mice, whereas CAFs from endoglin wild type mice 
could easily be propagated in vitro32. We observed that, although normal fibroblasts in vivo 
do not express endoglin, its expression is highly upregulated during cell culture. Despite its 
indispensability in vitro, the function of endoglin on CAFs can be further studied using 
neutralizing antibodies. 
In our in vitro assays, endoglin was important for CAF invasion through collagen-I. In 
endothelial cells, endoglin has been shown to be important for proliferation33 and 
migration34 and deletion of endoglin resulted in decreased Smad1 phosphorylation35. 
Recently, the crystal structure of BMP-9 bound to endoglin has been shown, revealing that 
endoglin is required to efficiently present BMP-9 to ALK117. This confirms our findings that in 
CAFs endoglin is essential for BMP-9-induced Smad1 phosphorylation. Decreased CAF 
invasion upon endoglin targeting might also partly be explained by increased ALK5 signaling, 
due to alleviation of the inhibition by the ALK1/endoglin complex, which was described in 
endothelial cells36. In accordance with this, we have recently observed increased Smad2 
phosphorylation in endothelial cells upon TRC105 treatment29. This phenomenon was not 
observed in CAFs, suggesting differences in TGF-β-/BMP-signaling between CAFs and 
endothelial cells, possibly by receptor abundance or expression of different type I receptors.  
In addition to formation of signaling complexes endoglin also interacts with integrins, crucial 
for adhesion and migration of ECs37. In fibroblasts, interactions between ECM and integrins 
were shown to be important for cellular migration38, but the role of endoglin in this 
interaction was not investigated. In our in vitro experiments, blocking endoglin function 
reduced CAF invasion through a collagen-I matrix, suggesting involvement of endoglin in 
degrading ECM, although the underlying mechanism remains elusive. 
The stimulatory role for endoglin in CAF invasion in vitro and its localization at the invasive 
border of colorectal tumors, suggests a role for endoglin-expressing CAFs in tumor 
metastasis. When we assessed lymph node and liver metastases from CRC patients, we 
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indeed observed the presence of endoglin positive CAFs in these lesions. Although 
contradictory findings have been published, co-migration of CAFs with CRC cells to the liver 
has been reported. Recently, Labernadie et al. revealed that CAFs use heterotypic cadherin 
interactions to interact with tumor cells and physically pull these cells out of the tumor mas 
in order to induce tumor invasion39. Endoglin interaction with VE-cadherin was reported in 
endothelial cells, in which VE-cadherin regulates cell migration40. Interactions of endoglin 
with other cadherins have not been reported yet, but might be involved in CAF-mediated 
tumor invasion through endoglin. The physical interaction of CAFs with tumor cells implies 
that CAFs could travel in a complex with tumor cells to metastatic sites. In accordance with 
this hypothesis, results from an experimental model for CRC metastasis showed that GFP 
expressing CAFs were localized in liver metastases and enhanced the formation of these 
lesions41. Also, in vivo experiments in a lung cancer model showed stromal cells derived from 
the primary tumor in metastatic lesions42. Together with our observation that TRC105 
inhibits specifically CAF-mediated liver metastasis in vivo, this implies that metastatic spread 
is, at least in part, regulated by endoglin.  
Previously, in prostate cancer models, it was shown that although endoglin heterozygosity 
increased primary tumor growth, the number of metastases was lower than wild type 
mice32. In contrast, increased metastatic spread of pancreatic tumors and subcutaneous 
implanted lung cancer cells has been reported in respectively endoglin heterozygous or 
endothelial specific endoglin KO mice43. Although this might seem contradictory to our 
findings, these studies investigated mostly endothelial endoglin expression and did not take 
fibroblast-specific endoglin into account. Heterozygous endoglin deletion in vivo results in a 
phenotype resembling hereditary hemorrhagic telangiectasia, including increased vascular 
permeability44, 45, possibly facilitating tumor cell intra- and extravasation and subsequently 
metastasis. Our current experiments specifically assessed the role of endoglin on CAFs. 
Moreover, unpublished data from our group showed that TRC105 treatment does not affect 
endothelial cell integrity in vitro. 
Interestingly, endoglin heterozygous prostate tumors presented as being non-fibrotic, and 
showed absence of αSMA expressing cells32. Moreover, we have previously shown that 
TRC105 treatment reduced metastatic spread, which was accompanied by a decreased 
αSMA-positive stromal content29. These observations imply a relevant role for CAF-specific 
endoglin expression in relation to metastatic spread. The fibrotic response is an important 
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regulator of tumor progression and metastasis46 and has been proposed as a prognostic 
factor in CRC47. Regarding endoglin, increased expression has been shown during cardiac 
fibrosis. Reduced endoglin expression or endoglin targeting prevented cardiac fibrosis in vivo 
and overexpression of soluble endoglin, acting as a ligand trap, reduced cardiac fibrosis48. 
These data combined with our observations that CAF-specific endoglin expression increases 
with increasing tumor stage, imply that endoglin could affect the fibrotic response and 
thereby further regulate tumor progression.  
 
In patients, we showed a correlation between high endoglin expression on CAFs at the 
invasive tumor borders and worse metastasis-free survival in stage-II CRC, implying the 
involvement of this CAF subset in tumor invasion and metastasis. Although the overall score 
of endoglin expression on CAFs in the stage-III cohort was higher than for stage-II, we did not 
find a correlation with metastasis-free survival of these patients. Since lymph node 
metastases are already present in stage-III patients, higher CAF specific endoglin expression 
would be expected and even suggests that these patients might have been identified during 
earlier stages based on high CAF-specific endoglin expression. 
 
In summary, the data presented here point to a crucial involvement of endoglin expressing 
CAFs in CRC invasion and metastasis and could therefore be a potential therapeutic target. 
Additionally, CAF-specific endoglin expression might be a novel prognostic factor in early 
stage CRC. In a phase I study, TRC105 showed clinical efficacy on pre-existing metastases in 
two patients 18. Combined with our recently published data that adjuvant TRC105 treatment 
decreased metastatic spread in breast cancer 29, targeting endoglin on CAFs, in addition to 
the endothelium, could be a potent approach in preventing metastasis formation. 
 
Acknowledgements 
This study was supported by the Alpe d’HuZes/Bas Mulder award 2011 (UL2011-5051), 
Stichting Fonds Oncologie Holland and Stichting Sascha Swarttouw-Hijmans to LH, MP and 
MS. We thank Dr. R. Fontijn for providing the ECRF cells, Lars Ottevanger (Dept. 
Gastroenterology-Hepatology, LUMC) for technical support and Hans van Dam, Marie-Jose 
Goumans (Dept. Molecular Cell Biology, LUMC), Hein Verspaget and Lennart van der Burg 
18 
 
(Dept, Gastroenterology-Hepatology, LUMC) for valuable discussions. TRC105 and M1043 





1. Ferlay J SI, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: 
IARC CancerBase No. 11 [Internet], Lyon, France: International Agency for Research on 
Cancer, Available from http://globocan.iarc.fr, accessed on 31/05/2016, 2013. 
2. Ahmed S, Johnson K, Ahmed O, et al. Advances in the management of colorectal cancer: from 
biology to treatment. Int J Colorectal Dis 2014;29:1031-42. 
3. Mesker WE, Junggeburt JM, Szuhai K, et al. The carcinoma-stromal ratio of colon carcinoma 
is an independent factor for survival compared to lymph node status and tumor stage. Cell 
Oncol 2007;29:387-398. 
4. Nyberg P, Salo T, Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci 
2008;13:6537-53. 
5. Herrera M, Islam AB, Herrera A, et al. Functional heterogeneity of cancer-associated 
fibroblasts from human colon tumors shows specific prognostic gene expression signature. 
Clin. Cancer Res 2013;19:5914-5926. 
6. Hawinkels LJ, Paauwe M, Verspaget HW, et al. Interaction with colon cancer cells 
hyperactivates TGF-beta signaling in cancer-associated fibroblasts. Oncogene 2014;33:97-
107. 
7. Tommelein J, Verset L, Boterberg T, et al. Cancer-associated fibroblasts connect metastasis-
promoting communication in colorectal cancer. Front Oncol 2015;5:63. 
8. Ronnov-Jessen L, Petersen OW, Koteliansky VE, et al. The origin of the myofibroblasts in 
breast cancer. Recapitulation of tumor environment in culture unravels diversity and 
implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 
1995;95:859-73. 
9. Lewis MP, Lygoe KA, Nystrom ML, et al. Tumour-derived TGF-beta1 modulates myofibroblast 
differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J 
Cancer 2004;90:822-32. 
10. Henriksson ML, Edin S, Dahlin AM, et al. Colorectal cancer cells activate adjacent fibroblasts 
resulting in FGF1/FGFR3 signaling and increased invasion. Am J Pathol 2011;178:1387-94. 
11. Li DY, Sorensen LK, Brooke BS, et al. Defective angiogenesis in mice lacking endoglin. Science 
1999;284:1534-1537. 
12. Carvalho RL, Jonker L, Goumans MJ, et al. Defective paracrine signalling by TGFbeta in yolk 
sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic 
telangiectasia. Development 2004;131:6237-6247. 
13. Arthur HM, Ure J, Smith AJ, et al. Endoglin, an ancillary TGFbeta receptor, is required for 
extraembryonic angiogenesis and plays a key role in heart development. Dev. Biol 
2000;217:42-53. 
14. Perez-Gomez E, Del CG, Juan FS, et al. The role of the TGF-beta coreceptor endoglin in 
cancer. ScientificWorldJournal 2010;10:2367-2384. 
15. Saad RS, Liu YL, Nathan G, et al. Endoglin (CD105) and vascular endothelial growth factor as 
prognostic markers in colorectal cancer. Mod. Pathol 2004;17:197-203. 
16. Akagi K, Ikeda Y, Sumiyoshi Y, et al. Estimation of angiogenesis with anti-CD105 




17. Saito T, Bokhove M, Croci R, et al. Structural Basis of the Human Endoglin-BMP9 Interaction: 
Insights into BMP Signaling and HHT1. Cell Rep 2017;19:1917-1928. 
18. Rosen LS, Hurwitz HI, Wong MK, et al. A Phase I First-in-Human Study of TRC105 (Anti-
Endoglin Antibody) in Patients with Advanced Cancer. Clin. Cancer Res 2012;18:4820-4829. 
19. Nolan-Stevaux O, Zhong W, Culp S, et al. Endoglin Requirement for BMP9 Signaling in 
Endothelial Cells Reveals New Mechanism of Action for Selective Anti-Endoglin Antibodies. 
PLoS. One 2012;7:e50920. 
20. Hawinkels LJ, Verspaget HW, van Duijn W, et al. Tissue level, activation and cellular 
localisation of TGF-beta1 and association with survival in gastric cancer patients. Br. J. Cancer 
2007;97:398-404. 
21. Hawinkels LJ, de Vinuesa AG, Paauwe M, et al. Activin Receptor-like Kinase 1 Ligand Trap 
Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid 
Tumors. Clin Cancer Res 2016;22:96-106. 
22. Corbett TH, Griswold DP, Jr., Roberts BJ, et al. Tumor induction relationships in development 
of transplantable cancers of the colon in mice for chemotherapy assays, with a note on 
carcinogen structure. Cancer Res 1975;35:2434-9. 
23. Fontijn R, Hop C, Brinkman HJ, et al. Maintenance of vascular endothelial cell-specific 
properties after immortalization with an amphotrophic replication-deficient retrovirus 
containing human papilloma virus 16 E6/E7 DNA. Exp Cell Res 1995;216:199-207. 
24. Hawinkels LJ, Kuiper P, Wiercinska E, et al. Matrix metalloproteinase-14 (MT1-MMP)-
mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 2010;70:4141-4150. 
25. Larsson J, Goumans MJ, Sjostrand LJ, et al. Abnormal angiogenesis but intact hematopoietic 
potential in TGF-beta type I receptor-deficient mice. EMBO J 2001;20:1663-73. 
26. Allinson KR, Carvalho RL, van den Brink S, et al. Generation of a floxed allele of the mouse 
Endoglin gene. Genesis 2007;45:391-5. 
27. Pardali E, van der Schaft DW, Wiercinska E, et al. Critical role of endoglin in tumor cell 
plasticity of Ewing sarcoma and melanoma. Oncogene 2011;30:334-345. 
28. Persson U, Izumi H, Souchelnytskyi S, et al. The L45 loop in type I receptors for TGF-beta 
family members is a critical determinant in specifying Smad isoform activation. FEBS Lett 
1998;434:83-7. 
29. Paauwe M, Heijkants RC, Oudt CH, et al. Endoglin targeting inhibits tumor angiogenesis and 
metastatic spread in breast cancer. Oncogene 2016;35:4069-79. 
30. Stoletov K, Montel V, Lester RD, et al. High-resolution imaging of the dynamic tumor cell 
vascular interface in transparent zebrafish. Proc Natl Acad Sci U S A 2007;104:17406-11. 
31. Paulsson J, Ehnman M, Ostman A. PDGF receptors in tumor biology: prognostic and 
predictive potential. Future. Oncol 2014;10:1695-1708. 
32. Romero D, O'Neill C, Terzic A, et al. Endoglin regulates cancer-stromal cell interactions in 
prostate tumors. Cancer Res 2011;71:3482-3493. 
33. Lebrin F, Goumans MJ, Jonker L, et al. Endoglin promotes endothelial cell proliferation and 
TGF-beta/ALK1 signal transduction. EMBO J 2004;23:4018-4028. 
34. Jonker L. TGF-beta & BMP receptors endoglin and ALK1: overview of their functional role and 
status as antiangiogenic targets. Microcirculation 2014;21:93-103. 
35. Lee NY, Ray B, How T, et al. Endoglin promotes transforming growth factor beta-mediated 
Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with 
GIPC. J Biol Chem 2008;283:32527-33. 
36. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Balancing the activation state of the 
endothelium via two distinct TGF-beta type I receptors. EMBO J 2002;21:1743-1753. 
37. Tian H, Mythreye K, Golzio C, et al. Endoglin mediates fibronectin/alpha5beta1 integrin and 
TGF-beta pathway crosstalk in endothelial cells. EMBO J 2012;31:3885-3900. 
38. Lobert VH, Brech A, Pedersen NM, et al. Ubiquitination of alpha 5 beta 1 integrin controls 




39. Labernadie A, Kato T, Brugues A, et al. A mechanically active heterotypic E-cadherin/N-
cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nat Cell Biol 2017;19:224-
237. 
40. Rudini N, Felici A, Giampietro C, et al. VE-cadherin is a critical endothelial regulator of TGF-
beta signalling. EMBO J 2008;27:993-1004. 
41. Gonzalez-Zubeldia I, Dotor J, Redrado M, et al. Co-migration of colon cancer cells and CAFs 
induced by TGFbeta(1) enhances liver metastasis. Cell Tissue Res 2015;359:829-39. 
42. Duda DG, Duyverman AM, Kohno M, et al. Malignant cells facilitate lung metastasis by 
bringing their own soil. Proc Natl Acad Sci U S A 2010;107:21677-82. 
43. Anderberg C, Cunha SI, Zhai Z, et al. Deficiency for endoglin in tumor vasculature weakens 
the endothelial barrier to metastatic dissemination. J. Exp. Med 2013;210:563-579. 
44. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of 
endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet 
1994;8:345-351. 
45. Jerkic M, Letarte M. Increased endothelial cell permeability in endoglin-deficient cells. FASEB 
J 2015;29:3678-88. 
46. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation 
and wound healing. N Engl J Med 1986;315:1650-9. 
47. Ueno H, Shinto E, Shimazaki H, et al. Histologic categorization of desmoplastic reaction: its 
relevance to the colorectal cancer microenvironment and prognosis. Ann Surg Oncol 
2015;22:1504-12. 
48. Kapur NK, Wilson S, Yunis AA, et al. Reduced endoglin activity limits cardiac fibrosis and 






Figure 1. CAF-specific endoglin expression in colorectal cancer 
A. Immunohistochemical staining of CRC tissue for cytokeratin, CD31, αSMA and endoglin. 
White arrowheads indicate high endoglin expression on the vasculature (CD31+/endoglin+). 
Black arrow heads show endoglin-expressing CAFs (αSMA+/endoglin+). Asterisks; αSMA+ 
smooth muscle cells surrounding vasculature. B. Immunofluorescent staining for endoglin 
(red) and αSMA (green) indicates high vascular endoglin expression and co-localization of 
αSMA and endoglin on CAFs (left panel). CRC tissue containing endoglin-negative CAFs was 
used to show staining specificity (right panel). C. Immunohistochemical staining for endoglin 
(left) and αSMA (right) in normal colonic mucosa, tumor core and invasive border of the 
same CRC patient. Asterisk indicates endoglin-positive blood vessels. 
 
Figure 2. CAF-specific endoglin expression at invasive border correlates to metastasis-free 
survival in stage-II CRC 
A. Primary tumor, lymph node and liver metastases from the same CRC patient show 
endoglin expressing CAFs (black arrow heads). White arrow heads; endothelial endoglin 
expression. B. Endoglin expression on CAFs at the invasive border of CRC correlates to 
metastasis-free survival in stage-II CRC patients (n=140), scored as either high or low 
(exemplified in upper boxes). C. Average score of CAF-specific endoglin expression in healthy 
tissue, polyps, stage-II and -III CRC patients. *p≤0.05, ***p≤0.001, ****p≤0.0001. 
 
Figure 3. BMP-9-induced signaling in CAFs is endoglin-dependent 
A. BMP-9 (0.1 ng/mL) stimulation of high endoglin expressing CAFs did not affect expression 
of PAI-1, but increased ID-1 expression. 5ng/mL TGF-β slightly increased ID-1 expression and 
highly stimulated PAI-1. Both ligands did not affect endoglin expression. B. BMP-9-
stimulation induced high pSmad1, whereas TGF-β showed slight induction. Endoglin protein 
expression was unaffected. C. Low endoglin expressing human CAFs showed the same 
response to TGF-β and BMP-9 for PAI-1, whereas BMP-9 stimulation failed to induce ID-1 
expression. Endoglin expression remained unaffected. D. Lack of BMP-9-induced pSmad1 in 
low endoglin expressing human CAFs. E. Mouse CAFs showed high induction of PAI-1 and ID-
1 after stimulation with TGF-β or BMP-9, respectively. Endoglin expression was unaffected. 
F. BMP-9-induced pSmad1 in mouse CAFs, without effects on endoglin protein expression. G. 
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shRNA-mediated endoglin knock down leads to cell death in human CAFs, while ECRF were 
unaffected. H. TGF-β-induced pSmad2 and pSmad1 was independent of TRC105 in human 
CAFs. BMP-9-induced pSmad1 was abrogated by TRC105. Endoglin-independent pSmad1 
induction by BMP-6 was unaffected by TRC105 treatment. I. In mouse CAFs, M1043 strongly 
decreased BMP-9-induced pSmad1. TGF-β increased pSmad2, which was unaffected by 
M1043. **p≤0.01, ***p≤0.001, **** p≤0.0001. pSmad1: phosphorylated Smad1; pSmad2: 
phosphorylated Smad2 
 
Figure 4. Endoglin regulates CAF invasive capacity in vitro 
A. Low (F1) and high (F2) endoglin-expressing CAFs were assessed for invasive properties. B. 
F2 CAFs invaded collagen-I matrix more extensively than F1 CAFs. Representative pictures of 
two experiments performed in triplicate. C. Endoglin overexpression increased expression 
more than 1000-fold. Representative graph of three independent experiments. D. Endoglin 
overexpression significantly enhanced CAF invasion after 24 hours in a transwell invasion 
assay. Data represent mean of three independent experiments, performed in triplicate. E. 
Reduced endoglin expression in endoglin KO MEFs (Endoglin KO). F. Endoglin KO significantly 
reduced MEF invasion in transwell invasion assays. Data represent mean of three 
independent experiments performed in triplicate. *≤0.05, **p≤0.01. 
 
Figure 5. Endoglin targeting inhibits CAF invasion in vitro 
A. M1043 significantly inhibited basal mouse CAF invasion, and induced a trend to reduced 
BMP-9- or TGF-β-mediated invasion. B. Mouse CAF invasion towards MC38 mouse CRC cells 
was significantly reduced in the presence of M1043, when compared to IgG control. C. 
TRC105 significantly inhibited basal human CAF invasion. F. Human CAF invasion towards the 
human CRC cell line HT29 was reduced upon treatment with TRC105, when compared with 
IgG control. All data represent mean of at least three independent experiments performed in 
triplicate. *p≤0.05, **p≤0.01, ****≤0.0001. 
 
Figure 6. Endoglin-expressing CAFs reduce survival in a novel zebrafish model for CRC 
A. Injection of dTomato MC38 cells, in presence or absence of MEFs, induces formation of 
solid tumors (red) and recruitment of vasculature (green) in zebrafish embryos. B. Co-
injection of MC38 cells with MEFs (MC38 + MEF) decreased survival in zebrafish embryos, 
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when compared to MC38 alone (n=24/group). C. Immunohistochemical staining showed 
vimentin-expressing MC38 cells invading the zebrafish liver. Co-injection with MEFs 
accelerated liver invasion (2 dpi, right panel) in comparison with MC38 alone (4 dpi, left 
panel). D. Co-injection of MC38 with endoglin KO MEFs resulted in similar fish survival when 
compared to injection of MC38 alone (n=23/group). E. Immunohistochemical staining of 
MC38 tumors for vimentin (MC38 cells) and αSMA (MEFs). *p≤0.05. dpi; days post injection. 
 
Figure 7. TRC105 inhibits CAF-mediated metastatic spread in a mouse model for liver 
metastasis 
A. Experimental set-up. Mice were injected with HT29 alone, or in combination with CAFs. 
Two days after injection, treatment with human IgG or TRC105 started. B. In vivo BLI to 
follow metastatic spread and quantified at indicated time points. TRC105 treatment reduced 
metastatic spread to the liver in mice injected with HT29 and CAFs (+CAFs TRC105). Graph 
represents two independent experiments, mean of 15 mice/group in total. C. TRC105 
treatment decreased ex-vivo BLI signal in livers of mice co-injected with HT29 and CAFs. D. 
Histological analysis of liver metastasis with H&E and staining for cytokeratin (HT29), αSMA 
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Supplementary figure S1 A. αSMA expression (green) on smooth muscle cell layer surrounding a large 
vessel. Endoglin (red) is specifically expressed by angiogenic endothelial cells within the endothelial layer. B. 

























Supplementary figure S2 Endoglin expression on CAFs at the invasive border does not correlate with survival in 
stage-III CRC. When endoglin expression on CAFs at the invasive borders was related to distant metastasis-free 










Supplementary figure S3 Fibroblasts in healthy colorectal tissue do not express endoglin. Healthy and tumor 
tissues from the same patient were stained for endoglin and αSMA to assess endoglin expression on (cancer-
associated) fibroblasts. αSMA-positive fibroblasts in healthy colonic tissue did not show endoglin expression. 
Pictures are representative for all patient tissues discussed in this manuscript. Tissue from patient #4, 
characterized in Table 1. 
A B 
Supplementary figure S4 Endoglin knock down in human endothelial cells. Short hairpin RNA constructs were 
introduced in human endothelial cells by lentiviral transduction. All constructs reduced endoglin expression at 
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Supplementary figure S5 HEK293T cells were transfected to express endoglin (A) and left to form 
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Supplementary figure S5 Characterization of TGF-β and BMP receptors in MEFs. After lentiviral transduction with 
a Cre recombinase expressing construct (ENG KO) or empty vector control (EV), cells were selected with 
puromycin. Effects of endoglin knock out on other receptors in TGF-β/BMP signaling were determined. Expression 
of endoglin, TGF-β type II receptor (TβRII), BMP type II receptor (BMPRII) and TGF-β type I receptor ALK-3 were 
significantly decreased upon Cre recombinase transduction. TGF-β type I receptor ALK-5 expression was not 
affected. αSMA levels did not change after Cre recombinase transduction. 
A B 
Supplementary figure S7 A. The presence of MC38 cells in the lower transwell compartment increased 
mouse CAF invasion to a similar extent as observed for BMP-9 stimulation. Addition of BMP-9 in the 
presence of MC38 did not further increase CAF invasion. B. The presence of HT29 human CRC cells strongly 














































Supplementary figure S8 Primary tumor formation and angiogenesis did not differ between MC38 alone, MC38 
co-injected with control MEFs or MC38 co-injected with endoglin KO MEFs.   
MC38 MC38 + MEF MC38 + KO MEF 
20x 
40x 
Endothelium MC38 
